PLVAP and infection: While the specificity to the PI4KB/OSBP pathway in terms of the anti-PV activity was clear, we could not exclude the potential contribution of the off-target effect of VCB (CC50 = 27 μM) to the observed anti-PV activity, which had quite a narrow therapeutic window (complete protection of the cells from PV1[Sabin 1] infection at 20 μM).